Molbio Diagnostics Limited has released its unaudited financial results for the second quarter and the first half of the fiscal year 2027, ending September 30, 2026. The company reported a Total Income of ₹265 Cr for Q2 FY27 and ₹676 Cr for H1 FY27. EBITDA stood at ₹50 Cr for Q2 FY27 and ₹153 Cr for H1 FY27, with PAT at ₹8 Cr and ₹60 Cr respectively.
Molbio Diagnostics Presents Q2 and H1 FY27 Financial Highlights
Molbio Diagnostics Limited has submitted its investor presentation detailing the unaudited financial results for the second quarter (Q2) and the first half (H1) of the fiscal year 2027, which concluded on September 30, 2026. This presentation provides key insights into the company’s financial performance during this period.
Q2 FY27 Performance Snapshot
For the second quarter of FY27, Molbio Diagnostics reported a Total Income of ₹265 Cr. The company’s EBITDA for the quarter was ₹50 Cr, with an EBITDA Margin of 18.8%. The Profit After Tax (PAT) for Q2 FY27 was ₹8 Cr, resulting in a PAT Margin of 2.9%. In terms of unit sales, 395 Truenat® devices were sold in Q2 FY27, and 3.2 million Truenat® test kits were sold.
H1 FY27 Performance Overview
During the first half of FY27, Molbio Diagnostics achieved a Total Income of ₹676 Cr. The EBITDA for H1 FY27 was ₹153 Cr, maintaining a healthy EBITDA Margin of 22.7%. The company’s PAT for the half-year stood at ₹60 Cr, with a PAT Margin of 8.9%. Sales figures for the first half include 559 Truenat® devices and 9.5 million Truenat® test kits sold.
Profit and Loss Trends
A quarterly review of the Profit & Loss statement shows varying trends. Total Income for Q2 FY27 was ₹264.8 Cr, a decrease from Q2 FY26’s ₹581.4 Cr but an increase from Q1 FY27’s ₹411.5 Cr. EBITDA for Q2 FY27 stood at ₹49.7 Cr, compared to ₹168.5 Cr in Q2 FY26 and ₹103.7 Cr in Q1 FY27. Consequently, Net Profit (PAT) for Q2 FY27 was ₹7.7 Cr, a significant drop from ₹106.8 Cr in Q2 FY26 and ₹52.7 Cr in Q1 FY27.
Half-Yearly Financial Comparison
Comparing the half-yearly results, H1 FY27 Total Income was ₹676.3 Cr, slightly lower than H1 FY26’s ₹681.8 Cr. EBITDA remained relatively stable at ₹153.4 Cr in H1 FY27 versus ₹153.2 Cr in H1 FY26. However, PAT saw a decrease from ₹82.9 Cr in H1 FY26 to ₹60.4 Cr in H1 FY27, impacting the PAT Margin from 12.2% to 8.9%.
Source: BSE
